Moore EM - Search Results

1

Clonal cytopenia of undetermined significance (CCUS) with dysplasia is enriched for MDS-type molecular findings compared to CCUS without dysplasia.

Jajosky AN, Sadri N, Meyerson HJ, Oduro KA Jr, Kelkar A, Fitzgerald B, Tomlinson B, Moore EM, Beck RC. Jajosky AN, et al. Among authors: moore em. Eur J Haematol. 2021 Apr;106(4):500-507. doi: 10.1111/ejh.13574. Epub 2021 Jan 15. Eur J Haematol. 2021. PMID: 33386622

2

Co-occurrence of type I CALR and two MPL mutations in patient with primary myelofibrosis.

Tashkandi H, Moore EM, Tomlinson B, Goebel T, Sadri N. Tashkandi H, et al. Among authors: moore em. Ann Hematol. 2017 Aug;96(8):1417-1418. doi: 10.1007/s00277-017-3022-x. Epub 2017 May 13. Ann Hematol. 2017. PMID: 28502030 No abstract available.

3

Erythroblastic sarcoma with rare PDGFRA rearrangement responding to tyrosine kinase inhibitor therapy.

Tomlinson B, Raess PW, Beck RC, Moore EM. Tomlinson B, et al. Among authors: moore em. Br J Haematol. 2020 Mar;188(6):e98-e100. doi: 10.1111/bjh.16379. Epub 2020 Jan 17. Br J Haematol. 2020. PMID: 31951668 Free article. No abstract available.

4

Clinical Utility of Targeted Next-Generation Sequencing in the Evaluation of Low-Grade Lymphoproliferative Disorders.

Jajosky AN, Havens NP, Sadri N, Oduro KA, Moore EM, Beck RC, Meyerson HJ. Jajosky AN, et al. Among authors: moore em. Am J Clin Pathol. 2021 Aug 4;156(3):433-444. doi: 10.1093/ajcp/aqaa255. Am J Clin Pathol. 2021. PMID: 33712839

5

Pathogenic Mutations and Atypical Flow Cytometric Findings Characterize the Majority of Unclassifiable Myelodysplastic/Myeloproliferative Neoplasms.

Li Y, Beck RC, Moore EM. Li Y, et al. Among authors: moore em. Am J Clin Pathol. 2021 Sep 8;156(4):634-643. doi: 10.1093/ajcp/aqaa281. Am J Clin Pathol. 2021. PMID: 33877292

6

Monoclonal B-cell lymphocytosis in the bone marrow: revisiting the criteria for chronic lymphocytic leukemia/small lymphocytic lymphoma.

Ryder CB, Oduro KA, Moore EM. Ryder CB, et al. Among authors: moore em. Hum Pathol. 2022 Jul;125:108-116. doi: 10.1016/j.humpath.2022.04.010. Epub 2022 Apr 25. Hum Pathol. 2022. PMID: 35472399

7

IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1+ and BCR::ABL1-like B-acute lymphoblastic leukaemia.

Gestrich CK, De Lancy SJ, Kresak A, Meyerson H, Pateva I, Yalley AK, Ryder C, Shetty S, Bledsoe J, Moore EM, Oduro KA Jr. Gestrich CK, et al. Among authors: moore em. Br J Haematol. 2024 Jan;204(1):229-239. doi: 10.1111/bjh.19142. Epub 2023 Oct 23. Br J Haematol. 2024. PMID: 37871900

8

Clonal Dynamics and Relapse Risk Revealed by High-Sensitivity FLT3-Internal Tandem Duplication Detection in Acute Myeloid Leukemia.

Oduro KA Jr, Spivey T, Moore EM, Meyerson H, Yoest J, Tomlinson B, Beck R, Alouani D, Sadri N. Oduro KA Jr, et al. Among authors: moore em. Mod Pathol. 2024 Sep;37(9):100534. doi: 10.1016/j.modpat.2024.100534. Epub 2024 Jun 7. Mod Pathol. 2024. PMID: 38852814 Free article.

9

Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms: A Multiparameter Study of a Rare and Aggressive Entity.

Bhavsar S, Liu YC, Gibson SE, Moore EM, Swerdlow SH. Bhavsar S, et al. Among authors: moore em. Am J Surg Pathol. 2022 Jan 1;46(1):71-82. doi: 10.1097/PAS.0000000000001750. Am J Surg Pathol. 2022. PMID: 34392269 Review.

10

Use of flow cytometry in the diagnosis of lymphoproliferative disorders in fluid specimens.

Yu GH, Vergara N, Moore EM, King RL. Yu GH, et al. Among authors: moore em. Diagn Cytopathol. 2014 Aug;42(8):664-70. doi: 10.1002/dc.23106. Epub 2014 Feb 19. Diagn Cytopathol. 2014. PMID: 24554583

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

156 results

Search Page

Filters